These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 747176)

  • 1. Naltrexone and conventionality.
    Suffet F; Remine DC; Taleporos E; Brotman R
    Am J Drug Alcohol Abuse; 1978; 5(2):221-33. PubMed ID: 747176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narcotic antagonist treatment: clinical experience with naltrexone.
    Lewis DC; Mayer J; Hersch RG; Black R
    Int J Addict; 1978 Aug; 13(6):961-73. PubMed ID: 730406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone treatment of heroin addiction: one-year follow-up.
    Judson BA; Goldstein A
    Drug Alcohol Depend; 1984 Jul; 13(4):357-65. PubMed ID: 6479015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Craving in heroin addicts maintained on the opiate antagonist naltrexone.
    Sideroff SI; Charuvastra VC; Jarvik ME
    Am J Drug Alcohol Abuse; 1978; 5(4):415-23. PubMed ID: 755381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.
    Jarvis BP; Holtyn AF; DeFulio A; Dunn KE; Everly JJ; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Addiction; 2017 May; 112(5):830-837. PubMed ID: 27936293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of naltrexone (EN-1639A): Part I: Safety and efficacy in pilot studies.
    Schecter AJ; Friedman JG; Grossman DJ
    Am J Drug Alcohol Abuse; 1974; 1(2):253-69. PubMed ID: 4467728
    [No Abstract]   [Full Text] [Related]  

  • 9. Five-year follow-up of opiate addicts with naltrexone and behavior therapy.
    Rawson RA; Tennant FS
    NIDA Res Monogr; 1984 Mar; 49():289-95. PubMed ID: 6434974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The combined use of scopolamine, naltrexone and naloxone as a rapid, safe and effective detoxification treatment for heroin addicts].
    Yang G; Zhou W; Xu K
    Zhonghua Yi Xue Za Zhi; 1999 Sep; 79(9):679-82. PubMed ID: 11715458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employment and social disability among opiate addicts.
    Suffet F; Brotman R
    Am J Drug Alcohol Abuse; 1976; 3(3):387-95. PubMed ID: 1032752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two naltrexone treatment programs: naltrexone alone versus naltrexone plus behavior therapy.
    Callahan E; Rawson R; Glazer M; McCleave B; Arias R
    NIDA Res Monogr; 1976 Sep; (9):150-7. PubMed ID: 794716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of naltrexone in 155 heroin ex-addicts.
    Volavka J; Resnick RB; Kestenbaum RS; Freedman AM
    Biol Psychiatry; 1976 Dec; 11(6):679-85. PubMed ID: 999987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing success in an antagonistic treatment program.
    Parwatikar S; Crawford J; Nelkupa JV; De Gracia C
    NIDA Res Monogr; 1976 Sep; (9):77-81. PubMed ID: 794725
    [No Abstract]   [Full Text] [Related]  

  • 16. The future of naltrexone.
    Renault PF
    NIDA Res Monogr; 1978; (19):340-5. PubMed ID: 106298
    [No Abstract]   [Full Text] [Related]  

  • 17. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone.
    Resnick RB; Kestenbaum RS; Washton A; Poole D
    Clin Pharmacol Ther; 1977 Apr; 21(4):409-13. PubMed ID: 849672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nontolerance to the opioid antagonism of naltrexone.
    Kleber HD; Kosten TR; Gaspari J; Topazian M
    Biol Psychiatry; 1985 Jan; 20(1):66-72. PubMed ID: 2981129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of naltrexone (EN 1639 A). Part II: experience with the first 50 patients in a New York City treatment clinic.
    Schecter A
    Am J Drug Alcohol Abuse; 1975; 2(3-4):433-42. PubMed ID: 1227301
    [No Abstract]   [Full Text] [Related]  

  • 20. Unreinforced self-injections: effects on rituals and outcome in heroin addicts.
    O'Brien CP; Greenstein R; Ternes J; McLellan AT; Grabowski J
    NIDA Res Monogr; 1979; 27():275-81. PubMed ID: 95035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.